Market Place
Sourcing Support
uniQure Reports Q3 2024 Results & Progress Update
05 Nov 2024 //
GLOBENEWSWIRE
uniQure Doses First Patient In Phase I/II Trial Of SOD1-ALS
15 Oct 2024 //
GLOBENEWSWIRE
UniQure Gets Orphan Drug Designation For AMT-191 In Fabry
23 Sep 2024 //
GLOBENEWSWIRE
uniQure Begins Dosing In Phase I/IIa Trial For Fabry Disease Treatment
15 Aug 2024 //
GLOBENEWSWIRE
uniQure Reports Q2 2024 Results And Company Update
01 Aug 2024 //
GLOBENEWSWIRE
UniQure, Arbutus, HilleVax Announce Layoffs
01 Aug 2024 //
FIERCE BIOTECH
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
23 Jul 2024 //
GLOBENEWSWIRE
UniQure Announces Data of Phase I/II Trials of AMT-130 for Huntington Disease
09 Jul 2024 //
GLOBENEWSWIRE
Genezen to Acquire uniQure’s Commercial Gene Therapy Operations in Lexington
02 Jul 2024 //
CONTRACT PHARMA
UniQure, with sale of plant, outsources Hemgenix manufacturing
02 Jul 2024 //
BIOPHARMADIVE
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
01 Jul 2024 //
GLOBENEWSWIRE
uniQure`s AMT-130 Gene Therapy Gets RMAT For Huntington`s Disease
03 Jun 2024 //
GLOBENEWSWIRE
uniQure Announces Q1 2024 Results And Company Progress
07 May 2024 //
GLOBENEWSWIRE
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
28 Feb 2024 //
GLOBENEWSWIRE
CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy
09 Feb 2024 //
ENDPTS
Uniqure Huntington`s gene therapy data `on the favorable side`
20 Dec 2023 //
FIERCE BIOTECH
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130
19 Dec 2023 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Dec 2023 //
GLOBENEWSWIRE
uniQure Announces FDA Clearance of IND Application for AMT-191
29 Nov 2023 //
GLOBENEWSWIRE
uniQure Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
CSL and uniQure Win 2023 Prix Galien USA Award
27 Oct 2023 //
PR NEWSWIRE
uniQure Announces Major Presence at the ESGCT Annual Meeting
24 Oct 2023 //
GLOBENEWSWIRE
UniQure lays off 5th of staff to fund gene therapy trials
06 Oct 2023 //
FIERCE BIOTECH
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Oct 2023 //
GLOBENEWSWIRE
uniQure Announces FDA Clearance of IND Application for AMT-260
05 Sep 2023 //
GLOBENEWSWIRE
uniQure Announces Second Quarter 2023 Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
uniQure Announces Leadership Addition to Support Advancement of Programs
26 Jun 2023 //
PRESS RELEASE
Gene therapy biotech uniQure`s stock sinks after hazy data drop
21 Jun 2023 //
FIERCE BIOTECH
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130A
21 Jun 2023 //
GLOBENEWSWIRE
uniQure announces achievement of $100 million milestone related to hemophilia B
20 Jun 2023 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Jun 2023 //
GLOBENEWSWIRE
UniQure sells part of Hemgenix royalty for $400M cash
16 May 2023 //
ENDPTS
uniQure Announces1Q 2023 FYR and Highlights Recent Company Progress
09 May 2023 //
GLOBENEWSWIRE
uniQure Announces Major Presence at Upcoming American Society of (ASGCT)
03 May 2023 //
BUSINESSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2023 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Mar 2023 //
GLOBENEWSWIRE
uniQure to Participate in Multiple Upcoming Industry Conferences in March
02 Mar 2023 //
GLOBENEWSWIRE
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
27 Feb 2023 //
GLOBENEWSWIRE
uniQure Announces HOPE-B Trial Data Published in New England Journal of Medicine
23 Feb 2023 //
GLOBENEWSWIRE
First Gene Therapy for Hemophilia B, CSL`s HEMGENIX, Approved by EC
21 Feb 2023 //
PR NEWSWIRE
uniQure and Apic Bio enter into global licensing agreement for APB-102
31 Jan 2023 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Dec 2022 //
GLOBENEWSWIRE
uniQure announces positive CHMP opinion for etranacogene dezaparvovec
16 Dec 2022 //
GLOBENEWSWIRE
CSL`s hemophilia B gene therapy works well through 24 months
12 Dec 2022 //
FIERCEPHARMA
Bristol Myers scraps uniQure cardiovascular gene therapy pact
30 Nov 2022 //
FIERCEBIOTECH
FDA approves first gene therapy for hemophilia B
23 Nov 2022 //
BIOPHARMADIVE
Australia`s CSL prices hemophilia gene therapy at $3.5 million
22 Nov 2022 //
REUTERS
uniQure to Host Virtual Research & Development Event on Tuesday
17 Nov 2022 //
GLOBENEWSWIRE
UniQure set to resume dosing in open-label Huntington`s trial
02 Nov 2022 //
FIERCEBIOTECH
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting (ESGCT)
11 Oct 2022 //
GLOBENEWSWIRE
uniQure to Participate in Upcoming Industry Conferences in October
03 Oct 2022 //
GLOBENEWSWIRE
uniQure to Participate in Upcoming Industry Conferences in September
06 Sep 2022 //
GLOBENEWSWIRE
3 patients hospitalized in uniQure Huntington`s disease trial
09 Aug 2022 //
FIERCEBIOTECH
uniQure Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
uniQure shares spike on Huntington`s gene therapy data
24 Jun 2022 //
FIERCEBIOTECH
uniQure: Update on Low-Dose Cohort in PI/II Trial of AMT-130 Gene Therapy
23 Jun 2022 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Jun 2022 //
GLOBENEWSWIRE
